Palm Beach Gardens, FL — November 18, 2025 — Leads & Copy — Curative Biotechnology Inc. (OTC: CUBT) has announced a strategic update, including a new partnership and changes to its capital structure, aimed at enhancing value creation for shareholders. The company, focused on novel treatments for degenerative eye diseases, is actively pursuing the most efficient path to advance its primary clinical program: metformin-based eye drops licensed from the National Eye Institute (NEI).
Curative Biotech plans to establish a strategic sublicense and manufacturing partnership for its metformin-based eye drops, which they believe will significantly de-risk trial operations, ensure a reliable supply chain, provide non-dilutive funding through upfront and clinical milestone payments, and accelerate commercialization for intermediate Dry Age-Related Macular Degeneration (AMD) and other degenerative eye diseases. The company is currently in negotiations with potential partners, with hopes to finalize an agreement before the end of the year. However, there is no guarantee that these negotiations will lead to a definitive agreement or that the transaction will close.
In addition to human applications, Curative Biotech will also focus on similar diseases in canines (K9), specifically Progressive Retinal Atrophy (PRA) and Central Progressive Retinal Atrophy (CPRA). CPRA, which closely mimics human Dry AMD, is eligible for the Minor Uses in Major Species accelerated approval pathway, potentially requiring a smaller, single 24-dog trial. Curative Biotech intends to pursue CPRA as the first K9 indication, along with human Dry AMD, using preclinical data from the human trial to support the application to the FDA Center for Veterinary Medicine (CVM). PRA will follow with a single effectiveness trial involving approximately 300 dogs.
The veterinary ophthalmic drug market is estimated to be worth between $1.5 billion and $2.0 billion annually. Both CPRA and PRA represent unmet medical needs; however, there is no assurance that the CVM will accept the company’s Dry AMD preclinical research as sufficient evidence of efficacy.
To align its capital structure with its updated strategic direction, Curative Biotech’s Board has decided to withdraw its planned S-1 public offering and has approved a revised 150-to-1 reverse stock split, replacing the previously planned 400-to-1 split. The reverse split is still subject to FINRA approval, which could take weeks or months, and there is no guarantee of approval or of any impact on the company’s capital needs.
Following the execution of the strategic sublicense/manufacturing agreement and completion of the reverse split, Curative Biotech plans to apply for uplisting to the OTCQB Venture Market, aiming for increased visibility and accessibility to investors, enhanced transparency, potential improvement in share liquidity, and positioning for a future uplisting to a national exchange. However, there is no assurance that the uplisting application will be accepted or that these objectives will be achieved.
Management and the Board say this new direction reflects a commitment to establishing a more sustainable, de-risked, and strategically aligned future for Curative Biotech, positioning the company for meaningful advancement of its clinical program and long-term value creation.
Interested shareholders and investors can request notifications of future press releases and updates by emailing ir@curativebiotech.com.
Curative Biotechnology, Inc. is focused on novel therapies for rare diseases. The company’s primary focus is its degenerative eye disease platform, supported by a worldwide exclusive license from the National Eye Institute (NEI) at the National Institutes of Health (NIH). The company is reformulating metformin for the treatment of Age-Related Macular Degeneration (AMD). A first-in-human clinical trial is targeted for 2026 under a Cooperative Research and Development Agreement (CRADA) with the NEI.
Contact:
Paul Michaels, Executive Chairman
Office: 917-492-8855
or
Investor Relations
ir@curativebiotech.com
Source: Curative Biotechnology Inc.
